These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11517841)

  • 1. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.
    Hall JA; Nelson MA; Meyer JW; Williamson T; Wagner S
    Manag Care Interface; 2001 Aug; 14(8):69-75. PubMed ID: 11517841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.
    Arikian SR; Casciano J; Doyle JJ; Tarride JE; Casciano RN
    Manag Care Interface; 2000 Feb; 13(2):88-94. PubMed ID: 11067391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
    Pradelli L; Iannazzo S
    J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
    Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
    Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
    Speakman M; Khullar V; Mundy A; Odeyemi I; Bolodeoku J
    Curr Med Res Opin; 2008 Aug; 24(8):2173-9. PubMed ID: 18565239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
    O'Brien BJ; Goeree R; Bernard L; Rosner A; Williamson T
    Clin Ther; 2001 Dec; 23(12):2038-49. PubMed ID: 11813937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 17. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 18. Patients with overactive bladders deserve better.
    Brenner B; Rice M
    N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
    Pelletier EM; Vats V; Clemens JQ
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.
    Getsios D; El-Hadi W; Caro I; Caro JJ
    Pharmacoeconomics; 2005; 23(10):995-1006. PubMed ID: 16235973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.